Your browser doesn't support javascript.
loading
A Phase II Study of Nivolumab plus Gemcitabine in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (KCSG HN17-11).
Jung, Hyun Ae; Park, Keon-Uk; Cho, Sanghee; Lim, Jinyeong; Lee, Keun-Wook; Hong, Min Hee; Yun, Tak; An, Ho Jung; Park, Woong-Yang; Pereira, Sergio; Ock, Chan-Young; Keam, Bhumsuk.
Afiliación
  • Jung HA; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
  • Park KU; Division of Hematology-Oncology, Department of Internal Medicine, Keimyung University Dongsan Hospital, Daegu, Republic of Korea.
  • Cho S; Division of Hematology-Oncology, Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Republic of Korea.
  • Lim J; Department of Health Sciences and Technology, Samsung Advanced Institute for Health Science and Technology, Sungkyunkwan University, Seoul, Republic of Korea.
  • Lee KW; Samsung Genome Institute, Samsung Medical Center, Sungkyunkwan University, Seoul, Republic of Korea.
  • Hong MH; Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
  • Yun T; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • An HJ; Division of Hematology-Oncology, Department of Internal Medicine, National Cancer Center, Goyang, Republic of Korea.
  • Park WY; Division of Oncology, Department of Internal Medicine, St. Vincent's Hospital, Suwon, Republic of Korea.
  • Pereira S; Department of Health Sciences and Technology, Samsung Advanced Institute for Health Science and Technology, Sungkyunkwan University, Seoul, Republic of Korea.
  • Ock CY; Samsung Genome Institute, Samsung Medical Center, Sungkyunkwan University, Seoul, Republic of Korea.
  • Keam B; Lunit, Seoul, Republic of Korea.
Clin Cancer Res ; 28(19): 4240-4247, 2022 10 03.
Article en En | MEDLINE | ID: mdl-35819451
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Nasofaríngeas / Nivolumab Tipo de estudio: Clinical_trials / Etiology_studies Límite: Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Nasofaríngeas / Nivolumab Tipo de estudio: Clinical_trials / Etiology_studies Límite: Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos